Hemab Therapeutics Holdings, Inc.COAG

NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Price (close)
$34.74
Market cap
$1.6B
P/E
—
Revenue (FY)
—
Net income
—
Dividend yield
—
1-year total return
—
Net margin
—
Revenue growth
—
Debt / equity
—

What Hemab Therapeutics Holdings, Inc. does.

No business description on file yet.

Revenue and profit, by fiscal year.

Fiscal year20242025

More on COAG.

Figures from Hemab Therapeutics Holdings, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.